Phase III Comparison of Vitespen, an Autologous Tumor-Derived Heat Shock Protein Gp96 Peptide Complex Vaccine, With Physician's Choice of Treatment for Stage IV Melanoma: The C-100-21 Study Group
Journal of Clinical Oncology - United States
doi 10.1200/jco.2007.11.9941
Full Text
Open PDFAbstract
Available in full text
Date
February 20, 2008
Authors
Publisher
American Society of Clinical Oncology (ASCO)